973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC

M.C. Garassino, S.M. Gadgeel, Giovanna Speranza et al. · Annals of Oncology · 2022

Cited by 31 works. doi:10.1016/j.annonc.2022.07.1101

Authors